Ocular Therapeutix Inc(OCUL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:45 PM ET (Korea 10/29 05:45)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.41 | Insider Own | 8.58% | Shs Outstand | 219.6M | Perf Week | 12.5% |
| Market Cap | 1.60B | Forward P/E | - | EPS next Y | 1.01% | Insider Trans | -0.57% | Shs Float | 200.8M | Perf Month | -7.37% |
| Enterprise Value | 1.08B | PEG | - | EPS next Q | -0.36 | Inst Own | 89.09% | Short Float | 14.33% | Perf Quarter | -13.93% |
| Income | -0.30B | P/S | 30.76 | EPS this Y | -5.38% | Inst Trans | 0.28% | Short Ratio | 9.47 | Perf Half Y | -20.85% |
| Sales | 0.05B | P/B | 3.08 | EPS next 5Y | 9.07% | ROA | -53.7% | Short Interest | 28.76M | Perf YTD | -39.95% |
| Book/sh | 2.37 | P/C | 2.67 | EPS past 3/5Y | -15.4% 11.13% | ROE | -72.99% | 52W High | -55.66% ($16.44) | Perf Year | -36.77% |
| Cash/sh | 2.73 | P/FCF | - | Sales past 3/5Y | 0.29% 24.45% | ROIC | -50.55% | 52W Low | 21.5% ($6.00) | Perf 3Y | 201.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -10.6% | Gross Margin | 87.11% | Volatility(W/M) | 4.79% 6.39% | Perf 5Y | 6.42% |
| Dividend TTM | - | EV/Sales | 20.78 | Sales Y/Y TTM | -8.14% | Oper. Margin | -603.04% | ATR (14) | 0.49 | Perf 10Y | 24.4% |
| Dividend Ex-Date | - | Quick Ratio | 13.03 | EPS Q/Q | 10.89% | Profit Margin | -579.1% | RSI (14) | 46.27 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.11 | Sales Q/Q | 0.12% | SMA20 | 3.86% ($7.02) | Beta | 1.2 | Target Price | $26.15 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/8/3 | SMA50 | -18.85% ($8.98) | Rel Volume | 0.94 | Prev Close | $6.72 |
| Employees | 325 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | 11.5% 2.07% | SMA200 | -20.36% ($9.15) | Avg Volume(3M) | 3.04M | Price | $7.29 |
| IPO | 2014/7/25 | Option/Short | Yes/Yes | Trades | 16557 | Volume | 2,845,534 | Change | 8.48% |
👁️ This is a US biotech company that develops and commercializes therapeutics for ophthalmic (eye) diseases. Leveraging its proprietary drug delivery technology that enables the slow release of medications, the company develops treatments for eye disorders and holds a commercialized product along with late-stage clinical candidates targeting conditions such as age-related macular degeneration. It has established itself as an ophthalmic biotech player by combining its sustained drug-release technology with its eye care pipeline.
Over the past 1 year, on the lower side
56% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
OCUL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -5.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,076. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +6.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 89.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #125 of 594 in the industry
Based on market cap of $2B.
URGN#122 UroGen Pharma Ltd $2B PER - 
TRAX#123 First Tracks Biotherapeutics Inc $2B PER - 
NUVB#124 Nuvation Bio Inc $2B PER - OCUL#125 Ocular Therapeutix Inc $2B PER - 
GPCR#126 Structure Therapeutics Inc ADR $2B PER - 
FAQ
What kind of company is OCUL?
OCUL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OCUL?
The market cap of OCUL is approximately $1.6B, ranking 2,256 within its sector.
What is the 52-week high and low for OCUL?
OCUL has recorded a 52-week high of $16.44 and a low of $6.00.
